Abstracts Archive - Page 2269 of 2607 - ACR Meeting Abstracts

Abstract Number: 2454 • 2013 ACR/ARHP Annual Meeting
High Prevalence Of Left Ventricular Diastolic Dysfunction In Patients With Ankylosing Spondylitis
Sjoerd C. Heslinga^1,2, Thelma C. Konings³, Irene E. Van der Horst-Bruinsma^4,5 and Michael T. Nurmohamed^1,2, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Cardiology, VU University Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Patients with ankylosing spondylitis (AS) have an increased cardiovascular risk leading to decreased life expectancy. This is due to both accelerated atherosclerotic disease as…
Abstract Number: 2455 • 2013 ACR/ARHP Annual Meeting
The Lipid Profile Improves In Patients With Ankylosing Spondylitis Responding To TNF Blocking Therapy
Sjoerd C. Heslinga^1,2, Irene E. Van der Horst-Bruinsma^3,4, Alper M. van Sijl^2,3 and Michael T Nurmohamed^1,5, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with ankylosing spondylitis (AS) have a decreased life expectancy due to an increased cardiovascular risk. Cardiovascular risk factors such as smoking, dyslipidemia, overweight,…
Abstract Number: 2456 • 2013 ACR/ARHP Annual Meeting
Prevalence Of Overweight and Obesity and The Relation To Disease Activity, Physical Function and Quality Of Life In Patients With Axial Spondyloarthritis
Fiona Maas¹, Anneke Spoorenberg¹, Eveline van der Veer², Reinhard Bos³, Monique Efde³, Hendrika Bootsma⁴, Elisabeth Brouwer⁵ and Suzanne Arends^3,4, ¹Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ²Laboratory Medicine, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology, Medical Center Leeuwarden, Leeuwarden, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Obesity is a growing problem in Western society. It is associated with an increased risk for many disorders, impaired functional capacity, and impaired quality…
Abstract Number: 2457 • 2013 ACR/ARHP Annual Meeting
Ankylosing Spondylitis and a Diagnostic Dilemma: Coccydynia
Rabia Deniz¹, Gülsen Ozen², Sibel Yilmaz-Oner², Sibel Z. Aydin³, Can Erzik⁴, Osman Hakan Gunduz⁵, Nevsun Inanc⁶, Haner Direskeneli² and Pamir Atagunduz⁶, ¹Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ³Unit of Rheumatology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey, ⁴Medical Biology, Marmara University School of Medicine, Istanbul, Turkey, ⁵Physical Medicine and Rehabilitation, Marmara University School of Medicine, Istanbul, Turkey, ⁶Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey
Background/Purpose: Coccydynia is defined as pain in or around the tail bone area. The most common cause of coccydynia is either a trauma such as…
Abstract Number: 2458 • 2013 ACR/ARHP Annual Meeting
Change Over Time In The Profile Of Ankylosing Spondylitis Patients Treated With Infliximab In Canadian Routine Care
Denis Choquette¹, Michael Starr², Majed M. Khraishi³, William G. Bensen⁴, Saeed A. Shaikh⁵, Jude F. Rodrigues⁶, Dalton E. Sholter⁷, Maqbool K. Sheriff⁸, Julie Vaillancourt⁹, John S. Sampalis⁹, Allen J. Lehman¹⁰, Susan M. Otawa¹⁰, Francois Nantel¹¹ and May Shawi¹², ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Montreal General Hospital, Montreal, QC, Canada, ³Nexus Clinical Research, St John's, NF, Canada, ⁴Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁵Medicine, McMaster University, St Catharines, ON, Canada, ⁶Rheumatology, Windsor, ON, Canada, ⁷Rheumatology Associates, Edmonton, AB, Canada, ⁸Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Canadian provincial reimbursement policies in regards with infliximab coverage status have evolved in the last decade. The objective of this study was to describe…
Abstract Number: 2459 • 2013 ACR/ARHP Annual Meeting
Improvement In Physical Function, Health-Related Quality Of Life, and Work Productivity With Adalimumab Treatment In Non-Radiographic Axial Spondyloarthritis
Désirée M. van Der Heijde¹, Philip J. Mease², Aileen L. Pangan³, Sumati A Rao³, Naijun Chen³ and Mary Cifaldi³, ¹Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³AbbVie Inc., North Chicago, IL
Background/Purpose: Adalimumab (ADA) was approved in the European Union for the treatment of severe non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation…
Abstract Number: 2460 • 2013 ACR/ARHP Annual Meeting
Spondyloarthritis Epidemiology and Burden Phase 2 [SPEED 2] Study: Disease Progression In Axial Spondyloarthropathy (SpA)
Eric Ruderman¹, Vibeke Strand², Avani Joshi³, Yanjun Bao³, Keith Betts⁴, Pooja Chopra⁴, Michael B. McGuire⁵ and Sumati A Rao³, ¹Northwestern University, Chicago, IL, ²Stanford University, Palo Alto, CA, ³AbbVie Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵Medical Data Analytics, Parsippany, NJ
Background/Purpose: Limited information is available on progression of non-radiographic axial spondyloarthropathy (nr-axSpA) to ankylosing spondylitis (AS) in patients with SpA meeting the Assessment of Spondyloarthritis…
Abstract Number: 2461 • 2013 ACR/ARHP Annual Meeting
Quality Of Life, Physical Function and Symptoms In Non-Radiographic Axial Spondyloarthritis:The Patient Perspective
Philip J. Mease¹, Sumati A Rao², Avani D. Joshi², Sarah Clifford³, Christina Vernon³ and Mary A. Cifaldi², ¹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ²AbbVie Inc., North Chicago, IL, ³United BioSource Corporation, Bethesda, MD
Background/Purpose: Pain, physical function impairment, and health-related quality of life (HRQoL) impact are substantial for patients with non-radiographic axial spondyloarthritis (nr-axSpA).1 Understanding the most important…
Abstract Number: 2462 • 2013 ACR/ARHP Annual Meeting
Comparison Of Tumor Necrosis Factor Inhibitor Use For Ankylosing Spondylitis At University Rheumatology Clinics In Scotland and Oregon
Anusha Reddy¹, Abhijeet Danve², Kiana Vakil-Gilani³, Jennifer H. Ku⁴, Sanjay Ganhasan⁵, Alison Black⁶ and Atul A. Deodhar³, ¹Rheumatology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom, ²Rheumatology, Oregon Health and Science University, Portland, OR, ³Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ⁴Arthritis and Rheumatic Diseases, Oregon Health and Science University, Portland, OR, ⁵Forresterhill Rd Aberdeen AB25 2ZN, United Kingdom, Aberdeen Royal Infirmary, Aberdeen, United Kingdom, ⁶Aberdeen Royal Infirmary, Aberdeen, United Kingdom
Background/Purpose: Use of tumor necrosis factor inhibitors (TNFi) for ankylosing spondylitis (AS) is directed by national guidelines in the UK. However in the US, in…
Abstract Number: 2463 • 2013 ACR/ARHP Annual Meeting
Tomosynthesis As a New Diagnostic Tool For Evaluation Of Ankylosing Spondylitis With Modified Stoke Ankylosing Spondylitis Spinal Score: A Comparison With Plain Radiographs
Seunghun Lee¹, Tae-Hwan Kim², Jae-Bum Jun², Kyung-Bin Joo³, Young Bin Joo⁴ and Jina Park⁵, ¹Department of Radiology, Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Department of Radiology, Department of Radiology, Hanynag University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁵Department of Radiology, Hanyang University Hospital, Seoul, South Korea
Background/Purpose: In assessment of ankylosing spondylitis (AS), accurate scoring of modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) is important to evaluate the treatment effects or…
Abstract Number: 2464 • 2013 ACR/ARHP Annual Meeting
Late-Onset Ankylosing Spondylitis Has Distinctive Presenting Symptoms and a Higher Inflammatory Burden
Yeon-Ah Lee¹, Sang-Hoon Lee², Ran Song², Hyung-In Yang² and Seung-Jae Hong¹, ¹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ²Rheumatology, Hospital at GANGDONG, Kyung Hee University, Seoul, South Korea
Background/Purpose: Most ankylosing spondylitis (AS) patients experience their first symptoms prior to age 45. However, symptoms of AS can develop after the age 45 and…
Abstract Number: 2465 • 2013 ACR/ARHP Annual Meeting
Prevelance Of Inflammatory Back Pain and Axial Spondyloarthritis Among University Employees In Izmir, Turkey
Fatos Onen¹, Dilek Solmaz¹, Pinar Cetin¹, Ali Balci², Servet Akar¹ and Nurullah Akkoc¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Radiology, Dokuz Eylul University School of Medicine, izmir, Turkey
Background/Purpose: The prevalence of axial spondyloarthritis (SpA) has not yet been investigated in a population based survey by using new ASAS classification criteria. The aim…
Abstract Number: 2466 • 2013 ACR/ARHP Annual Meeting
Long Term Efficacy Over Five Years Of Adalimumab In Patients With Active Non – Radiographic Axial Spondyloarthritis
Hildrun Haibel¹, Xenofon Baraliakos², Joachim Listing³, Juergen Braun⁴ and Joachim Sieper¹, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ³German Rheumatism Research Center, Berlin, Germany, ⁴Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Adalimumab had demonstrated good efficacy in 46 patients with active non-radiographic axial SpA in a 12-weeks, placebo-controlled trial with a 40-weeks, open-label extension.1,2In 19…
Abstract Number: 2467 • 2013 ACR/ARHP Annual Meeting
Response to Tumor Necrosis Factor inhibitors In Axial Spondyloarthritis: Does Sacroiliitis Make Any Difference?
Julien Girodon¹, Vianney Jouhet² and Elisabeth Solau-Gervais¹, ¹Rheumatology, University Hospital of Poitiers, Poitiers, France, ²Informatic, University hospital Bordeaux, Bordeaux, France
Background/Purpose: Axial spondyloarthritis (SpA) are characterized by sacroiliitis. The TNF inhibitors (TNFi) have been proven to be highly effective in ankylosing spondylitis. Recently, adalimumab demonstrate…
Abstract Number: 2468 • 2013 ACR/ARHP Annual Meeting
The Prevalence Of Sjogren’s Syndrome In Patients With Ankylosing Spondylitis
Ayse Balkarli¹, Adem Kucuk², Sahin Temel³, Tayfun Gungor⁴, Ramazan Ucar⁵ and Veli Cobankara⁶, ¹Department of Rheumatology, Pamukkale University School of Medicine, Denizli, Turkey, ²Necmettin Erbakan University, Meram Medical Faculty,Division of Rheumatology, Konya, Turkey, ³Department of Internal Medicine, Pamukkale University, Denizli, Turkey, ⁴Department of Physical medicine and Rehabilitation, Necmettin Erbakan University, Konya, Turkey, ⁵Konya Education and Research Hospital, Department ofInternal Medicine, Konya, Turkey, ⁶Division of Rheumatology, Pamukkale University, Denizli, Turkey
Background/Purpose : Sjögren's syndrome (SS) is a chronic autoimmune inflammatory disease that primarily affects exocrine glands with a prevalence of 1% to 4.8. SS mainly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].